Blood tests could fine-tune IBD treatment, saving money and improving lives

NCT ID NCT02508012

Completed Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether regularly measuring levels of anti-TNF drugs and antibodies in the blood can help doctors better manage inflammatory bowel disease (Crohn's and ulcerative colitis). 260 patients were split into two groups: one where doctors used these test results to adjust treatment, and one where they did not. The goal was to see if this monitoring approach improves quality of life and is cost-effective over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-TNF drugs (e.g., infliximab, adalimumab)
What this could lead to: If successful, this approach could help doctors adjust treatment more precisely, improving disease control and reducing costs for IBD patients.
What could go wrong: This is a completed study, not a new treatment. The monitoring strategy may not significantly improve outcomes or be cost-effective in all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE ULCERATIVE COLITIS

Contacts and locations

Locations

University hospital

Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.